Skip to main content

Peer Review reports

From: Plasma proteome signatures of ASK1 inhibition by selonsertib associate with efficacy in the MOSAIC randomized trial for diabetic kidney disease

Original Submission
10 Feb 2025 Submitted Original manuscript
25 Feb 2025 Author responded Author comments - Vladimir Petrovic
Resubmission - Version 2
25 Feb 2025 Submitted Manuscript version 2
6 Mar 2025 Author responded Author comments - Vladimir Petrovic
Resubmission - Version 3
6 Mar 2025 Submitted Manuscript version 3
10 Apr 2025 Reviewed Reviewer Report - Geoff Harley
10 Apr 2025 Reviewed Reviewer Report - Marie Ito
14 Apr 2025 Author responded Author comments - Vladimir Petrovic
Resubmission - Version 4
14 Apr 2025 Submitted Manuscript version 4
19 Apr 2025 Reviewed Reviewer Report - Geoff Harley
22 Apr 2025 Reviewed Reviewer Report - Marie Ito
29 Apr 2025 Author responded Author comments - Vladimir Petrovic
Resubmission - Version 5
29 Apr 2025 Submitted Manuscript version 5
6 May 2025 Author responded Author comments - Vladimir Petrovic
Resubmission - Version 6
6 May 2025 Submitted Manuscript version 6
Publishing
8 May 2025 Editorially accepted
15 May 2025 Article published 10.1186/s12882-025-04166-4

You can find further information about peer review here.

Back to article page